Potential impact of tuberculosis vaccines in China, South Africa, and India
To inform vaccine development decision making, we modeled the impact of hypothetical tuberculosis vaccines in three high-burden countries.
India
TbVacMod; Estimating the epidemiologic impact of new TB vaccines in high-burden settings
This is an NIH-funded study which will estimate the health impact of introducing a prevention of disease vaccine for adult and adolescents in moderate to high TB burden countries. We are developing model scenarios based on input from country stakeholders, including national TB program and immunization program officials.
Is neglect of self-clearance biasing TB vaccine impact estimates?
exploring the inclusion of self-clearance in models of tuberculosis affects the estimates of vaccine impact in China and India
Demand insights for uptake of TB vaccine
Summarize the major swing factors that would determine countries’ preference and effectively drive the uptake of a TB vaccine in terms of the date of introduction and the scale of catch-up campaign to reach the steady state
Bridging the gap: evaluating high TB burden country data needs to support the potential introduction of TB vaccines for adolescents and adults: a workshop report
A workshop to asked high TB burden country experts about what epidemiological, impact, feasibility and acceptability data they anticipated they would need to guide TB vaccine introduction.
Modelling the global burden of drug-resistant tuberculosis avertable by a post-exposure vaccine
Using mathematical models, we seek to estimate the potential impact of a post-exposure TB vaccine, having 50% efficacy in reducing active disease, on global rifampicin-resistant (RR-) TB burden.
Estimating the potential public health value of BCG revaccination
Using previously calibrated models for India and South Africa, we simulated BCG revaccination assuming 45% prevention-of-infection efficacy, and we evaluated scenarios varying additional prevention-of-disease efficacy between +50% (reducing risk) and −50% (increasing risk).
Meeting the 2030 End TB goals in the wake of COVID-19: a modelling study of countries in the USAID TB portfolio.
From 2023 onwards we modelled a combination of interventions acting at different stages of the care cascade, including improved diagnostics; reducing the patient care seeking delay; and the rollout of a disease-preventing vaccine from 2025 onwards.
Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries.
To aid in prioritizing the development of tuberculosis (TB) vaccines most likely to reach the 2050 TB elimination goal, we estimated the impact and cost-effectiveness of a range of vaccine profiles in low- and middle-income countries.
Potential implementation strategies, acceptability, and feasibility of new and repurposed TB vaccines
Our study provides crucial information for implementing novel TB vaccines in specific target groups and on country specific acceptability and feasibility. Key groups for vaccine implementation in these settings were identified, and should be included in clinical trials and implementation planning.